A US$50M Raise Positions Morphocell Technologies at the Center of Regenerative Medicine’s Next Phase
In an industry where clinical timelines stretch a decade and financing cycles can make or break scientific ambition, Morphocell Technologies has pulled off a milestone that places it among Canada’s most serious regenerative-medicine contenders. The Montreal-based biotechnology company has completed its full US$50 million Series A raise, adding a fresh US$10 million extension round led…
